Ray Prudo, MD, Executive Chairman
Click to read bio
Ray Prudo, M.D., has been an active investor and developer of healthcare companies for 25 years. Dr. Prudo was the Founder, Chairman, and Chief Executive Officer of Volution and its predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2008, joining Akari in September 2015 during the Volution/Celsus merger. He is currently a board member of several UK healthcare companies. Dr. Prudo holds an MBBS from the University of London, and an FRCP(C) from the Royal College of Physicians and Surgeons of Canada.
Contact: Ray.Prudo@akaritx.com
Clive Richardson, Interim Chief Executive Officer, Chief Operations Officer
Click to read bio
Clive Richardson was Head of Operations for Volution, and joined Akari in September 2015 during the Volution/Celsus merger. Prior to his role at Volution, Mr. Richardson served as consultant to Varleigh Immuno Pharmaceuticals since its inception in 2008. Prior to working for Volution and Varleigh, Mr. Richardson served as a member of the board of directors for a range of international healthcare companies, including CIS Healthcare Ltd. and Clinisys Ltd. Mr. Richardson was formerly Head of Equities Research for Investec Bank, and worked as a strategy consultant for L.E.K. Consulting. Mr Richardson holds an M.A. in Zoology from Trinity College, Oxford University.
Contact: clive.richardson@akaritx.com
Dov Elefant, Chief Financial Officer
Click to read bio
Dov Elefant was the Chief Financial Officer of Celsus Therapeutics from January 2012, and joined Akari in September 2015 during the Volution/Celsus merger. From March 2011 until January 2012, he was Chief Financial Officer of Althera Medical Ltd. and from March 2009 to February 2011 he performed consulting services to a number of companies. He was also the Corporate Controller, from March 2007 to February 2009 for Lev Pharmaceuticals (OTCBB:LEVP), which was acquired by ViroPharma in 2008,Controller and Vice President of Finance and Administration at EpiCept Corporation (NASDAQ:EPCT.PK) from December 1999 to March 2007,Assistant Controller at Tetragenex Pharmaceuticals from November 1998 to October 1999 and held other accounting and finance roles from March 1991 to October 1998. Mr. Elefant holds a B.S. in accounting from Yeshiva University.
Contact: Dov.Elefant@akaritx.com
Dr. Wynne Weston-Davies, Medical Director
Click to read bio
Wynne Weston-Davies, MRCS, LRCP, MB BS, FRCS, ECFMG, has 30 years of biopharmaceutical drug development experience, and was Medical Director of Volution since 2014, joining Akari in September 2015 during the Volution/Celsus merger. From 2009 to 2014, he served as the medical director at Varleigh. Prior to 2009, Dr. Weston-Davies was Medical Director for Evolutec Group Plc, a publicly-listed UK biotechnology company focused on the discovery and development of drugs from immuno-modulatory molecules found in the saliva of blood-feeding parasites. He has worked for a number of global pharmaceutical companies, including Bristol Myers Squibb from 1979-1992, where he headed up departments responsible for Phase I through Phase IV clinical trials. Dr. Weston-Davies has been a director of multiple health care companies, and initially worked as a general and colorectal surgeon at several UK teaching hospitals. Dr. Weston-Davies gained his initial medical qualifications at London University before becoming a Fellow of the Royal College of Surgeons.
Contact: wynne.weston-davies@akaritx.com
Dr. Miles Nunn, Chief Scientific Officer
Click to read bio
Miles Nunn was Chief Scientific Officer for Volution since April 2014, joining Akari in September 2015 during the Volution/Celsus merger. Prior to Volution, he worked at the Natural Environment Research Council (NERC) for 16 years. He discovered Volution’s lead drug, nomacopan (formerly Coversin), and is an inventor on several other patents. Dr. Nunn was formerly the Scientific Research Manager for Evolutec Group Plc, Director of Amplion Ltd., and a Principal Investigator for the Natural Environment Research Council. His scientific interests center on the structural and functional interactions between parasite-derived molecules and host defense responses, in particular complement, and on exploitation of the associated information and parasite molecules for drug development. Dr. Nunn holds a D.Phil. from Oxford University, and M.Sc. from University College London.
Contact: Miles.Nunn@akaritx.com
